Quick Asked: Travere Therapeutics Contact Us?
Last update: 27 Apr, 2024 
401 Views
What did travere therapeutics announce? SAN DIEGO, August 16, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN).How do i submit business development inquiries to travere therapeutics? If you would like to submit business development inquiries to Travere Therapeutics, please contact us at [email protected]. Any personal information you provide us will be processed according to our Privacy Policies. When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies.What is tratravere doing for rare revolution magazine? Travere is proud to collaborate with Rare Revolution Magazine on this issue. Ten years after being diagnosed with IgA nephropathy, a rare kidney disease, Stuart’s kidney function had depleted significantly. Today, after a lifesaving kidney donation from his wife, Stuart gives back to the kidney community through advocacy
Listing Results Travere Therapeutics Contact Us? Question Answers
Travere Therapeutics Home Facebook
(888) 969-7879 Travere Therapeutics Biotechnology Company in San Diego, California Closed Now CommunitySee All 70 people like this 82 people follow this AboutSee All 3611 Valley Centre Drive, Suite 300 (986.93 mi) San Diego, CA, CA 92130 Get Directions (888) 969-7879 Contact Travere Therapeutics on Messenger www.travere.com Biotechnology Company
Contact Us THIOLA (tiopronin) tablets
877-659-5518 Travere Therapeutics, Inc. 3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 Map To report a negative side effect to a Travere Therapeutics product, please call 877-659-5518. Side effects may also be reported to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. THIOLA EC ® (tiopronin) Important Safety Information
Travere Therapeutics, Inc. (TVTX) Company Profile
The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Travere Therapeutics
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement.
Kale Ruby's email & phone number Executive Director
View Kale Ruby's email address: rxxxxxxxe@ travere.com & phone: +1-909-xxx-xx48's profile as Executive Director, Development CMC at Travere Therapeutics Inc. at Travere Therapeutics, located in San Diego, California. Find contacts: direct phone number, email address, work experience.
Clinical Trials Privacy Policy Travere Therapeutics
+1-888-969-7879 You may contact us, Travere Therapeutics, Inc., via mail at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130, Attn: Chief Compliance Officer, via email at dataprotection@ travere.com, or you can call us at +1-888-969-7879.
Travere Therapeutics Email Formats & Employee Phones
Contact and general information about Travere Therapeutics company, headquarter location in San Diego, California. Email formats & phone numbers of Travere Therapeutics 200-500 employees. Biotech
Travere Therapeutics Overview, News & Competitors
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 74,900 shares of its ...
Corporate Privacy Policy Travere Therapeutics
+1-888-969-7879 We are Travere Therapeutics, Inc., and you can contact us via mail at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130, Attn: Chief Compliance Officer, via email at dataprotection@ travere.com, or you can call us at +1-888-969-7879.
RESTORE Study Cerebrotendinous Xanthomatosis (CTX
The goal of the RESTORE study is to better understand how the body responds, as measured in blood and urine, when people with CTX use CDCA. It will also help the sponsor (Travere Therapeutics, Inc.) learn more about the safety of CDCA, or what side effects, if ...
Travere Therapeutics, Inc. Company Profile San Diego, ...
Company Description: Travere Therapeutics, Inc. is located in San Diego, CA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Travere Therapeutics, Inc. has 262 total employees across all of its locations and generates $198.32 million in sales (USD). (Sales figure is estimated).
TRAVERE THERAPEUTICS, INC. Top 13F Holdings
888-969-7879 Contact Info travere therapeutics, inc. 3611 VALLEY CENTRE DR SAN DIEGO CA 92130 Business Phone: 888-969-7879
Peter Heerma's email & phone number Chief Commercial
View Peter Heerma's email address: hxxxxxxxxxxr@ travere.com & phone: +1-xxx-xxx-8335's profile as Chief Commercial Officer (CCO) at Travere Therapeutics, located in Los Angeles Metropolitan Area. Find contacts: direct ...
Contact Us – HCU Network America
HCU Network America has been established in the US as a non-profit with 501C(3) status so donations are tax deductible; our tax id number (EIN) is 81-3646006. Pages #GivingTuesday
CONTACT US Travere Therapeutics
Contact Travere Therapeutics by phone or by using this form. I understand that by checking this box and clicking "Submit", I am submitting my contact information and may receive company communications from Travere.
Contact Us Thiola
877-659-5518 Travere Therapeutics, Inc. 3721 Valley Centre Drive, Suite 200 San Diego, CA 92130 View map To report an adverse reaction, contact Travere Therapeutics, Inc. at 877-659-5518. Adverse ...
Travere Therapeutics Crunchbase Company Profile & ...
(646) 564-3680 Last Funding Type Post-IPO Equity. Also Known As Retrophin. Legal Name Travere Therapeutics, Inc. Stock Symbol NASDAQ:RTRX. Company Type For Profit. Contact Email partnering@ travere.com. Phone Number (646) 564-3680. Travere Therapeutics is advancing therapeutic candidates for rare disorders in nephrology, hepatology and metabolism; ...
Ulysses Diva Vice President Travere Therapeutics
View Ulysses Diva's business profile as Vice President at Travere Therapeutics. Find contact's direct phone number, email address, work history, and more.
IT Management Solutions & Consulting Services PCI
CFO, Travere Therapeutics “PCI’s Gap Assessment provided us with a roadmap to transform IT into a value-add for our organization. Since partnering with PCI we have increased our IT expertise, reduced areas of risk and increased IT operational efficiency: ...
Ulysses Diva Email Address Phone Number Travere
View the business profile and contact info for Ulysses Diva, Executive Director, Biometrics at Travere Therapeutics, Inc. in California, US. skip to main content We use cookies for marketing and advertising purposes, and to provide the best experience on our website. By continuing to browse the site, you agree to our use of cookies.
Website Cookies Policy Travere Therapeutics
+1-888-969-7879 Contact. If you have questions or concerns regarding our use of cookies you can contact us at dataprotection@ travere.com or +1-888-969-7879 or +1-858-832-2812 and ask for the Chief Compliance Officer. You can also find more information in our privacy policy. This Policy may be changed at any time by Travere Therapeutics. Last Updated: August 11
Travere Therapeutics, Inc.
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney ...